trazodone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2717	19794-93-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: trazodone trazodon trazodone hydrochloride trazodone HCl	A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309) Molecular weight: 371.87 Formula: C19H22ClN5O CLOGP: 3.85 LIPINSKI: 0 HAC: 6 HDO: 0 TPSA: 42.39 ALOGS: -3.11 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

trazodone
trazodon
trazodone hydrochloride
trazodone HCl

A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)

Molecular weight: 371.87
Formula: C19H22ClN5O
CLOGP: 3.85
LIPINSKI: 0
HAC: 6
HDO: 0
TPSA: 42.39
ALOGS: -3.11
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.30	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.20 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	23.05 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	81 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.52 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.08 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	7.30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 24, 1981	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	5345.32	41.17	1154	2810	19880	2334241
Toxicity to various agents	2853.85	41.17	766	3198	31988	2322133
Drug abuse	1399.45	41.17	358	3606	11668	2342453
Cardio-respiratory arrest	1159.21	41.17	292	3672	8854	2345267
Respiratory arrest	1065.70	41.17	253	3711	5925	2348196
Cardiac arrest	941.21	41.17	275	3689	14655	2339466
Serotonin syndrome	719.74	41.17	166	3798	3374	2350747
Overdose	664.38	41.17	226	3738	19681	2334440
Death	550.30	41.17	297	3667	81171	2272950
Drug hypersensitivity	496.47	41.17	232	3732	46411	2307710
Poisoning	487.09	41.17	116	3848	2704	2351417
Intentional overdose	301.27	41.17	109	3855	11212	2342909
Electrocardiogram QT prolonged	288.10	41.17	96	3868	7718	2346403
Suicide attempt	271.89	41.17	101	3863	11181	2342940
Hypotension	264.47	41.17	135	3829	32301	2321820
Somnolence	261.41	41.17	121	3843	23364	2330757
Coma	228.86	41.17	84	3880	8972	2345149
Intentional product misuse	214.10	41.17	81	3883	9408	2344713
Depressed level of consciousness	201.24	41.17	73	3891	7531	2346590
Drug interaction	169.18	41.17	97	3867	29066	2325055
Agitation	154.79	41.17	67	3897	10984	2343137
Insomnia	152.80	41.17	87	3877	25700	2328421
Asphyxia	150.95	41.17	37	3927	967	2353154
Drug ineffective	143.97	41.17	145	3819	101479	2252642
Torsade de pointes	143.14	41.17	42	3922	2204	2351917
Confusional state	135.82	41.17	79	3885	24265	2329856
Arteriosclerosis coronary artery	130.59	41.17	34	3930	1139	2352982
Exposure via ingestion	128.46	41.17	31	3933	757	2353364
Myocardial stunning	124.13	41.17	19	3945	25	2354096
Tremor	109.78	41.17	65	3899	20596	2333525
Hyperreflexia	109.46	41.17	28	3936	873	2353248
Mental status changes	105.67	41.17	42	3922	5540	2348581
Myoclonus	105.40	41.17	34	3930	2449	2351672
Mydriasis	104.97	41.17	33	3931	2186	2351935
Vomiting	104.43	41.17	104	3860	71498	2282623
Encephalopathy	102.95	41.17	39	3925	4522	2349599
Poisoning deliberate	101.72	41.17	28	3936	1163	2352958
Unresponsive to stimuli	100.42	41.17	39	3925	4837	2349284
Lethargy	96.84	41.17	45	3919	8685	2345436
Depression	96.08	41.17	67	3897	28065	2326056
Condition aggravated	95.09	41.17	70	3894	31909	2322212
Neuroleptic malignant syndrome	94.52	41.17	30	3934	2050	2352071
Accidental death	92.13	41.17	20	3944	299	2353822
Pulmonary congestion	92.02	41.17	29	3935	1936	2352185
Drug screen positive	89.65	41.17	24	3940	896	2353225
Sedation	84.08	41.17	31	3933	3331	2350790
Spleen congestion	82.84	41.17	14	3950	46	2354075
Aspiration	81.76	41.17	25	3939	1509	2352612
Hyponatraemia	81.57	41.17	46	3918	13279	2340842
Loss of personal independence in daily activities	80.20	41.17	34	3930	5277	2348844
Nausea	74.09	41.17	109	3855	112080	2242041
Aortic valve calcification	71.75	41.17	13	3951	70	2354051
Akathisia	67.28	41.17	22	3942	1652	2352469
Fatigue	67.16	41.17	90	3874	84783	2269338
Pulmonary oedema	66.58	41.17	33	3931	7330	2346791
Dry mouth	65.89	41.17	34	3930	8219	2345902
Fall	65.88	41.17	67	3897	47032	2307089
Respiratory depression	65.49	41.17	23	3941	2147	2351974
Cerebellar syndrome	65.42	41.17	17	3947	564	2353557
Disorientation	64.95	41.17	31	3933	6341	2347780
Delirium	64.42	41.17	29	3935	5194	2348927
Small for dates baby	63.09	41.17	17	3947	650	2353471
Medication error	63.02	41.17	30	3934	6101	2348020
Anxiety	62.87	41.17	53	3911	29306	2324815
Visual perseveration	60.74	41.17	11	3953	59	2354062
Metabolic acidosis	60.58	41.17	29	3935	5969	2348152
Generalised tonic-clonic seizure	60.50	41.17	28	3936	5344	2348777
Respiratory failure	57.60	41.17	37	3927	13491	2340630
Rhabdomyolysis	57.52	41.17	29	3935	6675	2347446
Bradycardia	57.14	41.17	33	3931	9948	2344173
Substance abuse	56.70	41.17	15	3949	534	2353587
Tachycardia	55.74	41.17	39	3925	16370	2337751
Syncope	54.76	41.17	39	3925	16836	2337285
Accidental poisoning	54.38	41.17	11	3953	114	2354007
Headache	54.37	41.17	79	3885	80100	2274021
Suicidal ideation	53.93	41.17	33	3931	11054	2343067
Muscle rigidity	53.70	41.17	19	3945	1812	2352309
Miosis	52.90	41.17	17	3947	1207	2352914
Accidental overdose	52.00	41.17	23	3941	3949	2350172
Intentional self-injury	51.16	41.17	23	3941	4104	2350017
Compartment syndrome	50.75	41.17	13	3951	407	2353714
Urinary tract infection	50.05	41.17	47	3917	29895	2324226
Sopor	48.68	41.17	22	3942	3973	2350148
Delusion	47.81	41.17	18	3946	2047	2352074
Apallic syndrome	47.00	41.17	10	3954	135	2353986
Constipation	46.17	41.17	39	3925	21590	2332531
Cardiomegaly	45.21	41.17	18	3946	2378	2351743
Off label use	44.83	41.17	69	3895	73529	2280592
Hyperhidrosis	44.03	41.17	33	3931	15389	2338732
Hypomagnesaemia	44.03	41.17	18	3946	2546	2351575
Purpura senile	42.69	41.17	7	3957	18	2354103
Inappropriate antidiuretic hormone secretion	42.36	41.17	17	3947	2292	2351829
Ventricular tachycardia	41.24	41.17	18	3946	2993	2351128

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	2187.12	46.99	556	2282	15756	1728187
Toxicity to various agents	1621.35	46.99	500	2338	28641	1715302
Priapism	1106.44	46.99	209	2629	1255	1742688
Drug abuse	1069.99	46.99	308	2530	13381	1730562
Serotonin syndrome	870.65	46.99	191	2647	2597	1741346
Cardio-respiratory arrest	534.57	46.99	166	2672	9127	1734816
Respiratory arrest	486.37	46.99	139	2699	5700	1738243
Cardiac arrest	424.76	46.99	160	2678	15770	1728173
Intentional overdose	325.40	46.99	109	2729	7561	1736382
Overdose	319.09	46.99	132	2706	16569	1727374
Death	266.94	46.99	206	2632	87237	1656706
Drug interaction	256.92	46.99	133	2705	27825	1716118
Electrocardiogram QT prolonged	235.62	46.99	79	2759	5466	1738477
Poisoning	217.83	46.99	62	2776	2470	1741473
Intentional product misuse	195.45	46.99	74	2764	7284	1736659
Suicide attempt	177.29	46.99	69	2769	7312	1736631
Somnolence	142.78	46.99	76	2762	16663	1727280
Agitation	138.09	46.99	65	2773	10961	1732982
Accidental overdose	136.72	46.99	49	2789	4115	1739828
Insomnia	125.11	46.99	69	2769	16207	1727736
Ventricular tachyarrhythmia	113.24	46.99	19	2819	47	1743896
Mental status changes	111.97	46.99	47	2791	6028	1737915
Hypotension	102.77	46.99	76	2762	29578	1714365
Myoclonus	98.46	46.99	33	2805	2262	1741681
Acute pulmonary oedema	96.48	46.99	28	2810	1189	1742754
Confusional state	95.69	46.99	64	2774	21214	1722729
Drug hypersensitivity	94.32	46.99	56	2782	15079	1728864
Unresponsive to stimuli	89.25	46.99	37	2801	4592	1739351
Shock	86.14	46.99	35	2803	4126	1739817
Anxiety	85.29	46.99	53	2785	15474	1728469
Muscle rigidity	84.96	46.99	28	2810	1820	1742123
Pneumonia aspiration	78.20	46.99	35	2803	5231	1738712
Lethargy	76.64	46.99	38	2800	7146	1736797
Coma	76.25	46.99	38	2800	7224	1736719
Tremor	72.53	46.99	45	2793	13086	1730857
Sedation	71.60	46.99	29	2809	3388	1740555
Bradycardia	70.89	46.99	41	2797	10493	1733450
Hypoglycaemia	68.07	46.99	37	2801	8401	1735542
Metabolic acidosis	67.96	46.99	32	2806	5370	1738573
Depression	65.06	46.99	46	2792	16623	1727320
Suicidal ideation	64.98	46.99	36	2802	8482	1735461
Exposure via ingestion	64.49	46.99	18	2820	662	1743281
Drug ineffective	64.45	46.99	83	2755	63718	1680225
Hyperreflexia	61.47	46.99	17	2821	604	1743339
Environmental exposure	60.77	46.99	11	2827	48	1743895
Symptom masked	57.99	46.99	11	2827	65	1743878
Depressed level of consciousness	56.21	46.99	30	2808	6562	1737381
Fall	54.79	46.99	51	2787	27163	1716780
Disorientation	52.65	46.99	27	2811	5442	1738501
Painful erection	52.62	46.99	11	2827	113	1743830
Poisoning deliberate	52.08	46.99	16	2822	826	1743117
Lactic acidosis	51.34	46.99	26	2812	5103	1738840
Acute kidney injury	51.03	46.99	55	2783	34889	1709054
Tachycardia	49.59	46.99	35	2803	12593	1731350
Dizziness	48.28	46.99	53	2785	34308	1709635
Hallucination, visual	47.51	46.99	20	2818	2572	1741371
Clonus	47.08	46.99	13	2825	459	1743484

Pharmacologic Action:

Source	Code	Description
ATC	N06AX05	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Other antidepressants
FDA EPC	N0000175696	Serotonin Reuptake Inhibitor
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D018687	Antidepressive Agents, Second-Generation
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D018490	Serotonin Agents
MeSH PA	D017367	Serotonin Uptake Inhibitors
CHEBI has role	CHEBI:35469	antidepressant
CHEBI has role	CHEBI:35717	sedative
CHEBI has role	CHEBI:37887	adrenergic antagonist
CHEBI has role	CHEBI:37955	H1-receptor antagonist
CHEBI has role	CHEBI:50949	serotonin uptake inhibitor
CHEBI has role	CHEBI:35474	anxiolytic drug
MeSH PA	D014149	Tranquilizing Agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Major depressive disorder	indication	370143000
Insomnia	off-label use	193462001
Priapism	contraindication	6273006	DOID:9286
Suicidal thoughts	contraindication	6471006
Orthostatic hypotension	contraindication	28651003
Torsades de pointes	contraindication	31722008
Hypokalemia	contraindication	43339004
Syndrome of inappropriate vasopressin secretion	contraindication	55004003	DOID:3401
Heart disease	contraindication	56265001	DOID:114
Blood coagulation disorder	contraindication	64779008	DOID:1247
Prolonged QT interval	contraindication	111975006
Hypomagnesemia	contraindication	190855004
Benign prostatic hyperplasia	contraindication	266569009
Myocardial infarction in recovery phase	contraindication	418044006
Congenital long QT syndrome	contraindication	442917000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	6.98	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
150MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	OLEPTRO	ANGELINI PHARMA	N022411	Feb. 2, 2010	DISCN	TABLET, EXTENDED RELEASE	ORAL	7829120	March 27, 2027	METHOD OF TREATING DEPRESSION
300MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	OLEPTRO	ANGELINI PHARMA	N022411	Feb. 2, 2010	DISCN	TABLET, EXTENDED RELEASE	ORAL	7829120	March 27, 2027	METHOD OF TREATING DEPRESSION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN	ANTAGONIST	Ki	6.65	WOMBAT-PK	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	ANTAGONIST	Ki	7.35	WOMBAT-PK	CHEMBL
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	Kd	6.80	WOMBAT-PK	CHEMBL
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	6.81	PDSP
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	6.03	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	6.75	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	5.90	DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.33	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Kd	5.13	WOMBAT-PK
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	6.21	WOMBAT-PK
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		IC50	9.55	WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.08	WOMBAT-PK
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	7.02	WOMBAT-PK
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Kd	5.07	WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5.54	WOMBAT-PK
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.58	WOMBAT-PK
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	6.15	PDSP
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN		Ki	5.75	PDSP
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	5.46	PDSP
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	5.43	PDSP
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN		Ki	6.97	PDSP
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.48	PDSP
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.21	DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	6.08	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	6.08	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR		5HT2A_RAT		IC50	7.77	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		Ki	6.65	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR		5HT2C_RAT	ANTAGONIST	Ki	6.70	IUPHAR
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	6.93	CHEMBL

External reference:

ID	Source
4019954	VUID
N0000148039	NUI
C0040805	UMLSCUI
D00820	KEGG_DRUG
6E8ZO8LRNM	UNII
25332-39-2	SECONDARY_CAS_RN
7336002	SNOMEDCT_US
4019954	VANDF
10737	RXNORM
372829000	SNOMEDCT_US
004610	NDDF
d00395	MMSL
CHEMBL621	ChEMBL_ID
DB00656	DRUGBANK_ID
CHEMBL1200798	ChEMBL_ID
CHEBI:9654	CHEBI
2878	INN_ID
D014196	MESH_DESCRIPTOR_UI
5533	PUBCHEM_CID
213	IUPHAR_LIGAND_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0733	TABLET	300 mg	ORAL	ANDA	19 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0603-6160	TABLET, FILM COATED	50 mg	ORAL	ANDA	20 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0603-6161	TABLET, FILM COATED	100 mg	ORAL	ANDA	20 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-2578	TABLET	50 mg	ORAL	ANDA	14 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-2579	TABLET	100 mg	ORAL	ANDA	14 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8155	TABLET	150 mg	ORAL	ANDA	19 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6554	TABLET	50 mg	ORAL	ANDA	19 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6555	TABLET	100 mg	ORAL	ANDA	19 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6868	TABLET	50 mg	ORAL	ANDA	19 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6869	TABLET	100 mg	ORAL	ANDA	19 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-532	TABLET	100 mg	ORAL	ANDA	20 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-533	TABLET	150 mg	ORAL	ANDA	14 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-534	TABLET	50 mg	ORAL	ANDA	19 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-867	TABLET	150 mg	ORAL	ANDA	20 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	12634-193	TABLET, FILM COATED	50 mg	ORAL	ANDA	21 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13107-079	TABLET	50 mg	ORAL	ANDA	19 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13107-080	TABLET	100 mg	ORAL	ANDA	19 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13107-081	TABLET	150 mg	ORAL	ANDA	19 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13107-082	TABLET	300 mg	ORAL	ANDA	19 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13668-330	TABLET	50 mg	ORAL	ANDA	19 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13668-331	TABLET	100 mg	ORAL	ANDA	19 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13668-332	TABLET	150 mg	ORAL	ANDA	19 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13668-333	TABLET	300 mg	ORAL	ANDA	19 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16590-231	TABLET	50 mg	ORAL	ANDA	14 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16590-232	TABLET	100 mg	ORAL	ANDA	14 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16590-585	TABLET	150 mg	ORAL	ANDA	14 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-299	TABLET	50 mg	ORAL	ANDA	19 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-300	TABLET	100 mg	ORAL	ANDA	19 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-301	TABLET	150 mg	ORAL	ANDA	19 sections
Trazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-302	TABLET	300 mg	ORAL	ANDA	19 sections